Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 594
- Registration Number
- NCT01505114
- Locations
- ๐บ๐ธ
Weill Cornell Chelsea CRS, New York, New York, United States
๐บ๐ธNew Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States
๐บ๐ธUCLA CARE Center CRS, Los Angeles, California, United States
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
- Conditions
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Bruce Brew
- Target Recruit Count
- 19
- Registration Number
- NCT01449006
- Locations
- ๐ฆ๐บ
St. Vincent's Hospital, Sydney, New South Wales, Australia
๐ฆ๐บThe Alfred Hospital, Melbourne, Victoria, Australia
Safety Study of Maraviroc's Effect on Human Osteoclasts
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2014-09-25
- Target Recruit Count
- 16
- Registration Number
- NCT01428986
- Locations
- ๐ฏ๐ต
National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 262
- Registration Number
- NCT01400412
- Locations
- ๐บ๐ธ
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States
๐บ๐ธUniv. of South Florida (USF) College of Medicine ATN CRS (33001), Tampa, Florida, United States
๐บ๐ธWashington U CRS (2101), Saint Louis, Missouri, United States
Maraviroc Abacavir STudy - Effect on Endothelial Recovery
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- S.F.L. van Lelyveld
- Target Recruit Count
- 24
- Registration Number
- NCT01389063
- Locations
- ๐ณ๐ฑ
University Medical Center Utrecht, Utrecht, Netherlands
Maraviroc Switch Collaborative Study
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 399
- Registration Number
- NCT01384682
- Locations
- ๐ฆ๐ท
Fundacion IDEAA, Buenos Aires, Argentina
๐ฆ๐ทHospital Privado- Centro Medico Cordoba, Cordoba, Argentina
๐ฆ๐บHoldsworth House Medical Practice, Sydney, New South Wales, Australia
The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT01348763
- Locations
- ๐ฌ๐ง
Imperial College Healthcare NHS Trust, London, United Kingdom
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 813
- Registration Number
- NCT01345630
- Locations
- ๐บ๐ธ
Circle CARE Center, Norwalk, Connecticut, United States
๐ซ๐ทCHU de Nantes - Hotel Dieu, Nantes, France
๐บ๐ธHealth Services Center, Hobson City, Alabama, United States
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 138
- Registration Number
- NCT01327547
- Locations
- ๐บ๐ธ
AIDS Research Alliance, Los Angeles, California, United States
๐บ๐ธGeorgia Regents Medical Center, Augusta, Georgia, United States
๐บ๐ธSaint Michael's Medical Center, Newark, New Jersey, United States
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT01290211
- Locations
- ๐ง๐ช
Pfizer Investigational Site, Bruxelles, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.